<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Intracardiac <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> are a potential source of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The disposition of intracardiac <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> in <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>/<z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> (<z:hpo ids='HP_0002326'>TIA</z:hpo>) patients was investigated over a 10-month period using omniplanar transesophageal echocardiography (TEE) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: One hundred and five patients underwent TEE examination at &lt;1 month and again at 9-12 months (mean 10 months) after symptom <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>TEEs were evaluated for <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> in the left atrium, left atrial appendage and left ventricle </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> risk factors and TEE findings were compared between patients with and without new <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> on follow-up TEE </plain></SENT>
<SENT sid="5" pm="."><plain>Similar comparisons were made in patients with and without disappearance of <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> on the follow-up TEE </plain></SENT>
<SENT sid="6" pm="."><plain>The effect of <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> was evaluated </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Intracardiac <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were found initially in 18% (95% CI 11-25%) of patients in 79% (95% CI 61-97%) of whom the <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> disappeared on the follow-up TEE; this significantly correlated with <z:chebi fb="8" ids="10033">warfarin</z:chebi> anticoagulation (p = 0.037) </plain></SENT>
<SENT sid="8" pm="."><plain>In the remainder 82% (95% CI 75-89%) patients, new <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were detected on the follow-up TEE in 8% (2-14%) </plain></SENT>
<SENT sid="9" pm="."><plain>These were older (p = 0.009), and not on anticoagulation </plain></SENT>
<SENT sid="10" pm="."><plain>Patients with aortic atheroma &gt;/=4 mm were also more likely to develop new intracardiac <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> (p = 0.001) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Anticoagulation with <z:chebi fb="8" ids="10033">warfarin</z:chebi> for 10 months is associated with conditions leading to disappearance of intracardiac <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> after a cerebral ischemic event and hence has a probable therapeutic role </plain></SENT>
<SENT sid="12" pm="."><plain>Older patients, not anticoagulated, and those with significant aortic atheroma &gt;/=4 mm may have increased probability for de novo <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> development </plain></SENT>
<SENT sid="13" pm="."><plain>These patients may be at risk of cardiac embolization and could be considered for prophylactic anticoagulation </plain></SENT>
</text></document>